Kymera Therapeutics (KYMR) grants CLO Brian Adams options and RSUs

Rhea-AI Filing Summary

Kymera Therapeutics reported that Chief Legal Officer Brian Adams received new equity awards. He was granted a stock option for 8,250 shares at an exercise price of $0.00 per share, and 4,125 shares of common stock in the form of restricted stock units. The RSUs vest in four equal annual installments following March 2, 2026, while the stock option vests in 48 equal monthly installments following the same date, in each case contingent on continued employment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Adams Brian

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,250	$0.00	--
Grant/Award	Common Stock	4,125	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,250 shares (Direct); Common Stock — 56,625 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Brian

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		4,125(1)	A	$0	56,625	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$90.1	03/02/2026		A		8,250		(2)	03/01/2036	Common Stock	8,250	$0	8,250	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

2. The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kymera Therapeutics (KYMR) report for Brian Adams?

Kymera Therapeutics reported that Chief Legal Officer Brian Adams received equity awards. He was granted 8,250 stock options and 4,125 restricted stock units on March 2, 2026, as part of his compensation, all subject to future vesting conditions tied to continued employment.

How many stock options did Brian Adams receive from Kymera Therapeutics (KYMR)?

Brian Adams received a grant of 8,250 stock options. These options carry an exercise price of $0.00 per share and will vest in forty-eight equal monthly installments after March 2, 2026, provided he remains employed through each applicable vesting date.

What are the terms of the restricted stock units granted to Brian Adams at Kymera (KYMR)?

Brian Adams was granted 4,125 restricted stock units, each representing one share of common stock upon vesting and settlement. The RSUs vest in four equal annual installments following March 2, 2026, conditioned on his continued employment through each vesting date.

When do Brian Adams’ stock options at Kymera Therapeutics (KYMR) vest?

The stock options granted to Brian Adams vest in forty-eight equal monthly installments. Vesting begins after March 2, 2026, and continues monthly, with each installment contingent on his continued employment at Kymera Therapeutics through the relevant vesting date.

When do Brian Adams’ RSUs from Kymera Therapeutics (KYMR) vest?

Brian Adams’ restricted stock units vest in four equal annual installments. These installments occur after March 2, 2026, with each tranche requiring that he remain employed at Kymera Therapeutics through the corresponding annual vesting date before shares are delivered.

What is Brian Adams’ Kymera (KYMR) share ownership after this Form 4 filing?

Following the reported RSU grant, Brian Adams beneficially owns 56,625 shares of Kymera common stock. This figure reflects his direct ownership after the March 2, 2026 equity awards, combining previously held shares with the newly granted restricted stock units.

Are Brian Adams’ new Kymera (KYMR) equity awards immediately exercisable or payable?

No, the awards are subject to vesting schedules. The restricted stock units vest in four equal annual installments, and the stock options vest in forty-eight equal monthly installments, all following March 2, 2026, and conditioned on Brian Adams’ continued employment.